Fig. 1From: Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6CV risk score* according to metformin use at baseline. The light gray color indicates the overlap between the metformin and no-metformin subgroups. *Derived from a prediction model developed using independent data sets from the liraglutide CV outcomes trial and previously applied to SUSTAIN 6 and PIONEER 6 [19]. CV cardiovascularBack to article page